Main Article Content
treated by agonists of gonadotropinâ€‘releasing hormone. Triptoreline salts are the first therapeutics of this group
launched into the market in the form of microparticles (microspheres). Implants, as one of attractive injectable dosage
forms, have many advantages over multiâ€‘particulate systems. Some of these advantages are dose adjustability, drug absorption improvement, constant release profile, etc. In this research, a new composite of polyâ€‘lacticâ€‘coâ€‘glycolic acid and hyaluronic acid was designed and prepared in the form of implants containing triptorelin acetate for administration as an injection under the skin (subcutaneously) in arm or thigh area. The manufactured implants characterized by Fourier transform infrared spectroscopy, thermas gravimetric analysis, Xâ€‘ray diffraction and scanning electron microscopy to assess different aspects of structure and morphology. The drug release profile was assessed by high performance liquid chromatography. These
characterizations confirmed that the newly designed drug delivery has a good stability during manufacturing process. The
release pattern of the implant was also studied and revealed that the release of the model drug follows a zeroâ€‘order and
erosion mechanism. The compatibility between the components of the newly designed implants and the release profile of
the delivery system make it a promising device for drug delivery.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
Shaw G, Oliver RT. Intermittent hormone therapy and its place in the
contemporary endocrine treatment of prostate cancer. Surg Oncol
Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, et al. Hormone replacement
therapy and ovarian cancer risk: A metaâ€‘analysis. Gynecol Oncol
Martin LJ, Minkin S, Boyd NF. Hormone therapy, mammographic density,
and breast cancer risk. Maturitas 2009;64:20â€‘6.
Staren ED, Omer S. Hormone replacement therapy in postmenopausal
women. Am J Surg 2004;188:136â€‘49.
Cutler WB, Genoveseâ€‘Stone E. Wellness in women after 40 years of age:
The role of sex hormones and pheromones. Dis Mon 1998;44:421â€‘546.
Murad MH, Elamin MB, Garcia MZ, Mullan RJ, Murad A, Erwin PJ,
et al. Hormonal therapy and sex reassignment: A systematic review
and metaâ€‘analysis of quality of life and psychosocial outcomes. Clin
Handelsman DJ, Zajac JD. 11: Androgen deficiency and replacement
therapy in men. Med J Aust 2004;180:529â€‘35.
Bolar K, Hoffman AR, Maneatis T, Lippe B. Longâ€‘term safety of
recombinant human growth hormone in turner syndrome. J Clin
Endocrinol Metab 2008;93:344â€‘51.
Akehurst RL, Barnett D, Berry SC, Bird S, Buxton M, Claxton K, et al.
Guidance on the use of human growth hormone (somatropin) in
children with growth failure. Technology Appraisal Guidance No. 42 National Institute for Clinical Excellence. 2002.
Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr. Effects of
thyroxine as compared with thyroxine plus triiodothyronine in patients
with hypothyroidism. N Engl J Med 1999;340:424â€‘9.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin 2011;61:69â€‘90.
Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M. An overview
on 5alphaâ€‘reductase inhibitors. Steroids 2010;75:109â€‘53.
Kraus S, Naor Z, Seger R. Gonadotropinâ€‘releasing hormone in apoptosis
of prostate cancer cells. Cancer Lett 2006;234:109â€‘23.
Giteau A, Venierâ€‘Julienne MC, Aubertâ€‘Pouessel A, Benoit JP. How to
achieve sustained and complete protein release from PLGAâ€‘based
microparticles? Int J Pharm 2008;350:14â€‘26.
Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable
poly (lacticâ€‘coâ€‘glycolic acid) microparticles for injectable delivery of
vaccine antigens. Adv Drug Deliv Rev 2005;57:391â€‘410.
Powell EM, Sobarzo MR, Saltzman WM. Controlled release of nerve
growth factor from a polymeric implant. Brain Res 1990;515:309â€‘11.
Yasukawa T, Kimura H, Tabata Y, Ogura Y. Biodegradable scleral plugs
for vitreoretinal drug delivery. Adv Drug Deliv Rev 2001;52:25â€‘36.
Fournier E, Passirani C, Monteroâ€‘Menei CN, Benoit JP. Biocompatibility
of implantable synthetic polymeric drug carriers: Focus on brain
biocompatibility. Biomaterials 2003;24:3311â€‘31.
Nitsch MJ, Banakar UV. Implantable drug delivery. J Biomater Appl
Shi Y, Li LC. Current advances in sustainedâ€‘release systems for parenteral
drug delivery. Expert Opin Drug Deliv 2005;2:1039â€‘58.
Iyer SS, Barr WH, Karnes HT. Profiling in vitro drug release from
subcutaneous implants: A review of current status and potential
implications on drug product development. Biopharm Drug Dispos
Hetrick EM, Prichard HL, Klitzman B, Schoenfisch MH. Reduced foreign
body response at nitric oxideâ€‘releasing subcutaneous implants.
Ratner BD. Reducing capsular thickness and enhancing angiogenesis
around implant drug release systems. J Control Release 2002;78:211â€‘8.
McTaggart LE, Halbert GW. Assessment of polysaccharide gels as drug
delivery vehicles. Int J Pharm 1993;100:199â€‘206.
Coviello T, Matricardi P, Marianecci C, Alhaique F. Polysaccharide
hydrogels for modified release formulations. J Control Release
Xu X, Jha AK, Duncan RL, Jia X. Heparinâ€‘decorated, hyaluronic acidâ€‘based
hydrogel particles for the controlled release of bone morphogenetic
proteinâ€‘2. Acta Biomater 2011;7:3050â€‘9.
Tammi R, Ã…gren UM, Tuhkanen AL, Tammi M. Hyaluronan metabolism
in skin. Prog Histochem Cytochem 1994;29:1â€‘81.
Trommer H, Wartewig S, BÃ¶ttcher R, PÃ¶ppl A, Hoentsch J, Ozegowski JH,
et al. The effects of hyaluronan and its fragments on lipid models
exposed to UV irradiation. Int J Pharm 2003;254:223â€‘34.
Sadighi A, Ostad SN, Rezayat SM, Foroutan M, Faramarzi MA,
Dorkoosh FA. Mathematical modelling of the transport of
hydroxypropylâ€‘betaâ€‘cyclodextrin inclusion complexes of ranitidine
hydrochloride and furosemide loaded chitosan nanoparticles across a
Cacoâ€‘2 cell monolayer. Int J Pharm 2012;422:479â€‘88.
Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release
from controlled drug delivery systems. Acta Pol Pharm 2010;67:217â€‘23.
Higuchi T, Connors KA, Phaseâ€‘solubility techniques. Adv Anal Chem
Korsmeyer RW, Gumy R, Doelker E, Buri P, Peppas NA. Mechanisms of solute
release from porous hydrophilic polymers. Int J Pharm 1983;15:25â€‘35.
Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms
of drug release in poly (lacticâ€‘coâ€‘glycolic acid)â€‘based drug delivery
systemsâ€‘â€‘a review. Int J Pharm 2011;415:34â€‘52.